Phase I/II trial of T cell therapy [OvaSave; TxCell] in patients with Crohn's disease.

Trial Profile

Phase I/II trial of T cell therapy [OvaSave; TxCell] in patients with Crohn's disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Regulatory T lymphocyte cell therapy-OvaSave (Primary)
  • Indications Crohn's disease
  • Focus First in man; Therapeutic Use
  • Acronyms CATS-1
  • Most Recent Events

    • 26 May 2016 Novel mechanism of action data will be presented at the International Society for Cell Therapy (ISCT) 2016 Annual Meeting, as per TxCell media release.
    • 25 Oct 2012 Results from the 1-year extension trial were presented at the 20th United European Gastroenterology Week (UEGW 2012) in October 2012.
    • 21 Feb 2012 Results were presented at the 7th European Crohn's and Colitis Organization (ECCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top